These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27542210)

  • 21. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
    Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
    Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
    Id Said B; Kim H; Tran J; Novokmet A; Malkin D
    Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.
    Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ
    Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline TP53 mutations and Li-Fraumeni syndrome.
    Varley JM
    Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing Fatty Acid Oxidation Improves Cancer-free Survival in a Mouse Model of Li-Fraumeni Syndrome.
    Wang PY; Ma J; Li J; Starost MF; Wolfgang MJ; Singh K; Pirooznia M; Kang JG; Hwang PM
    Cancer Prev Res (Phila); 2021 Jan; 14(1):31-40. PubMed ID: 32958587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant p21WAF1-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li-Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations.
    Barley RD; Enns L; Paterson MC; Mirzayans R
    Oncogene; 1998 Aug; 17(5):533-43. PubMed ID: 9704919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing.
    Zampiga V; Danesi R; Tedaldi G; Tebaldi M; Cangini I; Pirini F; Pittureri C; Amaducci E; Guidi L; Faedi M; Amadori D; Falcini F; Calistri D
    Int J Biol Markers; 2016 Dec; 31(4):e461-e465. PubMed ID: 27516001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds.
    Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K
    Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional characterization of novel germline TP53 variants in Swedish families.
    Kharaziha P; Ceder S; Axell O; Krall M; Fotouhi O; Böhm S; Lain S; Borg Å; Larsson C; Wiman KG; Tham E; Bajalica-Lagercrantz S
    Clin Genet; 2019 Sep; 96(3):216-225. PubMed ID: 31081129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
    Gu J; Kawai H; Wiederschain D; Yuan ZM
    Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.
    Bougeard G; Renaux-Petel M; Flaman JM; Charbonnier C; Fermey P; Belotti M; Gauthier-Villars M; Stoppa-Lyonnet D; Consolino E; Brugières L; Caron O; Benusiglio PR; Bressac-de Paillerets B; Bonadona V; Bonaïti-Pellié C; Tinat J; Baert-Desurmont S; Frebourg T
    J Clin Oncol; 2015 Jul; 33(21):2345-52. PubMed ID: 26014290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Li-Fraumeni syndrome.
    Chompret A
    Biochimie; 2002 Jan; 84(1):75-82. PubMed ID: 11900879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.
    Zhou R; Xu A; Gingold J; Strong LC; Zhao R; Lee DF
    Trends Pharmacol Sci; 2017 Oct; 38(10):908-927. PubMed ID: 28818333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome.
    Shlien A; Tabori U; Marshall CR; Pienkowska M; Feuk L; Novokmet A; Nanda S; Druker H; Scherer SW; Malkin D
    Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11264-9. PubMed ID: 18685109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.
    Kratz CP; Achatz MI; Brugières L; Frebourg T; Garber JE; Greer MC; Hansford JR; Janeway KA; Kohlmann WK; McGee R; Mullighan CG; Onel K; Pajtler KW; Pfister SM; Savage SA; Schiffman JD; Schneider KA; Strong LC; Evans DGR; Wasserman JD; Villani A; Malkin D
    Clin Cancer Res; 2017 Jun; 23(11):e38-e45. PubMed ID: 28572266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel germline TP53 mutation p.Pro190Arg detected in a patient with lung and bilateral breast cancers.
    Krześniak M; Butkiewicz D; Rachtan J; Matuszczyk I; Grzybowska E; Rusin M
    Adv Med Sci; 2017 Sep; 62(2):207-210. PubMed ID: 28499267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
    Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Li-Fraumeni syndrome: update, new data and guidelines for clinical management].
    Frebourg T; Abel A; Bonaiti-Pellie C; Brugières L; Berthet P; Bressac-de Paillerets B; Chevrier A; Chompret A; Cohen-Haguenauer O; Delattre O; Feingold J; Feunteun J; Frappaz D; Fricker JP; Gesta P; Jonveaux P; Kalifa C; Lasset C; Leheup B; Limacher JM; Longy M; Nogues C; Oppenheim D; Sommelet D; Soubrier F; Stoll C; Stoppa-Lyonnet D; Tristant H
    Bull Cancer; 2001 Jun; 88(6):581-7. PubMed ID: 11459705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a rare polymorphism in the human TP53 promoter.
    Attwooll CL; McGown G; Thorncroft M; Stewart FJ; Birch JM; Varley JM
    Cancer Genet Cytogenet; 2002 Jun; 135(2):165-72. PubMed ID: 12127401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.